Adverum Biotechnologies Announces Updated Presentation Time for ARM 5th Annual Cell & Gene Therapy Investor Day

MENLO PARK, Calif., April 17, 2017 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. ADVM, a leading gene therapy company advancing novel medicines to address unmet needs in serious rare and ocular diseases, announced today that the Company's presentation time at the Alliance for Regenerative Medicine's 5^th Annual Cell & Gene Therapy Investor Day has been changed. Amber Salzman, Ph.D., president and chief executive officer, will now present at 4:15 pm EDT.

A live and replay video webcast of the presentation will be available at http://www.arminvestorday.com/webcast.

About Adverum Biotechnologies, Inc.

Adverum is a gene therapy company advancing novel medicines that can offer life-changing benefits to patients living with serious rare and ocular diseases. Adverum has a robust pipeline that includes product candidates designed to treat wet age-related macular degeneration (wAMD) and rare diseases alpha-1 antitrypsin (A1AT) deficiency and hereditary angioedema (HAE).  Leveraging a next-generation adeno-associated virus (AAV)-based directed evolution platform, the Company generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum has collaboration agreements with Regeneron Pharmaceuticals to research, develop, and commercialize gene therapy products for ophthalmic diseases and Editas Medicine to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases. Adverum's core capabilities include clinical development and in-house manufacturing expertise, specifically in process development and assay development. For more information please visit www.adverum.com.

Contacts for Adverum:

Leone Patterson
Chief Financial Officer
Adverum Biotechnologies, Inc.
650-665-7222
lpatterson@adverum.com

Jill Steier
Senior Vice President
The Trout Group LLC
646-378-2946
jsteier@troutgroup.com